AU2022291150A1 - Radioimmunoconjugates and checkpoint inhibitor combination therapy - Google Patents

Radioimmunoconjugates and checkpoint inhibitor combination therapy Download PDF

Info

Publication number
AU2022291150A1
AU2022291150A1 AU2022291150A AU2022291150A AU2022291150A1 AU 2022291150 A1 AU2022291150 A1 AU 2022291150A1 AU 2022291150 A AU2022291150 A AU 2022291150A AU 2022291150 A AU2022291150 A AU 2022291150A AU 2022291150 A1 AU2022291150 A1 AU 2022291150A1
Authority
AU
Australia
Prior art keywords
alkyl
antigen
antibody
kbq
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022291150A
Other languages
English (en)
Inventor
Eric Steven BURAK
Natalie GRINSHTEIN
Meiduo HU
Julie METCALF
John Fitzmaurice Valliant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Pharmaceuticals Inc
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of AU2022291150A1 publication Critical patent/AU2022291150A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022291150A 2021-06-11 2022-06-10 Radioimmunoconjugates and checkpoint inhibitor combination therapy Pending AU2022291150A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163209736P 2021-06-11 2021-06-11
US63/209,736 2021-06-11
PCT/US2022/033058 WO2022261467A1 (en) 2021-06-11 2022-06-10 Radioimmunoconjugates and checkpoint inhibitor combination therapy

Publications (1)

Publication Number Publication Date
AU2022291150A1 true AU2022291150A1 (en) 2023-12-21

Family

ID=84426354

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022291150A Pending AU2022291150A1 (en) 2021-06-11 2022-06-10 Radioimmunoconjugates and checkpoint inhibitor combination therapy

Country Status (13)

Country Link
US (1) US20240285818A1 (https=)
EP (1) EP4351662A1 (https=)
JP (1) JP2024521418A (https=)
KR (1) KR20240021227A (https=)
CN (1) CN117794585A (https=)
AR (1) AR126128A1 (https=)
AU (1) AU2022291150A1 (https=)
BR (1) BR112023026076A2 (https=)
CA (1) CA3222948A1 (https=)
IL (1) IL309243A (https=)
MX (1) MX2023014778A (https=)
TW (1) TW202317204A (https=)
WO (1) WO2022261467A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4577527A1 (en) * 2022-08-22 2025-07-02 Abdera Therapeutics Inc. Vhh antibody dota conjugates
KR20250171285A (ko) * 2023-04-12 2025-12-08 코넬 유니버시티 암 치료용 방사선치료 접합체

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7922998B2 (en) * 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds

Also Published As

Publication number Publication date
EP4351662A1 (en) 2024-04-17
CN117794585A (zh) 2024-03-29
BR112023026076A2 (pt) 2024-03-05
WO2022261467A1 (en) 2022-12-15
IL309243A (en) 2024-02-01
CA3222948A1 (en) 2022-12-15
WO2022261467A9 (en) 2023-05-04
JP2024521418A (ja) 2024-05-31
KR20240021227A (ko) 2024-02-16
US20240285818A1 (en) 2024-08-29
TW202317204A (zh) 2023-05-01
AR126128A1 (es) 2023-09-13
MX2023014778A (es) 2024-01-15

Similar Documents

Publication Publication Date Title
AU2019393257A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
JP7191938B2 (ja) Ｉｇｆ－１ｒモノクローナル抗体及びその使用
ES2861499T3 (es) Anticuerpos anti-B7-H3 y conjugados anticuerpo-fármaco
JP2023090748A (ja) 二官能性キレートの薬物動態増強及びその使用
CN110997725A (zh) 抗-il1rap抗体和抗体药物缀合物
HK1255483A1 (zh) 抗体和免疫结合物
US20250121104A1 (en) Egfr-cmet-targeted compounds and uses thereof
AU2022291150A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
CA3167285A1 (en) Sustained immunotherapy
TW202304532A (zh) 治療癌症之方法
JP2023518818A (ja) Ｆｇｆｒ３に標的化されたラジオイムノコンジュゲートおよびその使用
HK40058366A (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
HK40109328A (zh) 放射免疫缀合物及检查点抑制剂组合疗法
HK40060346A (en) Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
HK40118862A (zh) 抗-il1rap抗体和抗体药物缀合物
HK40027179B (zh) 抗-il1rap抗体和抗体药物缀合物
HK40027179A (en) Anti-il1rap antibodies and antibody drug conjugates
TW201729827A (zh) 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合